Treace(US:TMCI) GlobeNewswire News Roomยท2025-06-06 14:20Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of misleading statements and failure to disclose important information regarding competition and revenue guidance [3][5]. Group 1: Allegations Against Treace Medical - The complaint alleges that Treace Medical and its executives violated federal securities laws by making false and misleading statements [5]. - Key issues include the impact of competition on the demand for Treace's primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5]. - The company had to accelerate plans for an alternative product to osteotomy due to competitive pressures [5]. Group 2: Revenue Guidance and Stock Impact - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from $220 million-$225 million to $201 million-$211 million [6]. - Following this announcement, the company's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [7]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][9]. - There is a June 10, 2025 deadline for investors to seek the role of lead plaintiff in the federal securities class action against Treace Medical [3].